Nuvation Bio Inc. Research and Development Expense
Nuvation Bio Inc. (NUVB) reported Research and Development Expense of $30.66 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- Nuvation Bio Inc. research and development expense for the quarter ending 2026-06-30 was $30.66M, a 12.06% increase year-over-year.
- Nuvation Bio Inc. research and development expense for the quarter ending 2026-03-31 was $35.05M, a 42.46% increase year-over-year.
- Nuvation Bio Inc. research and development expense for the quarter ending 2025-12-31 was $34.30M, a 17.06% increase year-over-year.
- Nuvation Bio Inc. research and development expense for the quarter ending 2025-09-30 was $28.85M, a 4.02% increase year-over-year.
- Nuvation Bio Inc. research and development expense for fiscal 2025 was $115.11M, a 16.13% increase from fiscal 2024.
- Nuvation Bio Inc. research and development expense for fiscal 2024 was $99.12M, a 39.04% increase from fiscal 2023.
- Nuvation Bio Inc. research and development expense for fiscal 2023 was $71.29M, a 18.82% decline from fiscal 2022.
- Nuvation Bio Inc. research and development expense for fiscal 2022 was $87.81M, a 27.20% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $30.66M 10-Q · filed 2026-08-06 | $65.71M 10-Q · filed 2026-08-06 | $100.00M derived: sum of 3 quarters · filed 2026-08-06 | $128.85M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $35.05M 10-Q · filed 2026-05-04 | $69.34M derived: sum of 2 quarters · filed 2026-05-04 | $98.19M derived: sum of 3 quarters · filed 2026-05-04 | $125.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $34.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $63.14M derived: sum of 2 quarters · filed 2026-03-02 | $90.50M derived: sum of 3 quarters · filed 2026-08-06 | $115.11M 10-K · filed 2026-03-02 |
| 2025-09-30 | $28.85M 10-Q · filed 2025-11-03 | $56.21M derived: sum of 2 quarters · filed 2026-08-06 | $80.81M 10-Q · filed 2025-11-03 | $110.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $27.36M 10-Q · filed 2026-08-06 | $51.96M 10-Q · filed 2026-08-06 | $81.26M derived: sum of 3 quarters · filed 2026-08-06 | $108.99M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $24.60M 10-Q · filed 2026-05-04 | $53.90M derived: sum of 2 quarters · filed 2026-05-04 | $81.63M derived: sum of 3 quarters · filed 2026-05-04 | $110.88M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $29.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $57.03M derived: sum of 2 quarters · filed 2026-03-02 | $86.28M derived: sum of 3 quarters · filed 2026-03-02 | $99.12M 10-K · filed 2026-03-02 |
| 2024-09-30 | $27.73M 10-Q · filed 2025-11-03 | $56.98M derived: sum of 2 quarters · filed 2025-11-03 | $69.82M 10-Q · filed 2025-11-03 | $85.17M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $29.25M 10-Q · filed 2025-08-07 | $42.09M 10-Q · filed 2025-08-07 | $57.44M derived: sum of 3 quarters · filed 2025-08-07 | $76.00M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $12.84M 10-Q · filed 2025-05-07 | $28.19M derived: sum of 2 quarters · filed 2025-05-07 | $46.75M derived: sum of 3 quarters · filed 2025-05-07 | $65.34M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $15.35M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $33.91M derived: sum of 2 quarters · filed 2025-03-06 | $52.50M derived: sum of 3 quarters · filed 2025-03-06 | $71.29M 10-K · filed 2025-03-06 |
| 2023-09-30 | $18.56M 10-Q · filed 2024-11-06 | $37.15M derived: sum of 2 quarters · filed 2024-11-06 | $55.94M 10-Q · filed 2024-11-06 | $72.81M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $18.59M 10-Q · filed 2024-08-05 | $37.38M 10-Q · filed 2024-08-05 | $54.25M derived: sum of 3 quarters · filed 2024-08-05 | $75.54M derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | $18.79M 10-Q · filed 2024-05-14 | $35.66M derived: sum of 2 quarters · filed 2024-05-14 | $56.95M derived: sum of 3 quarters · filed 2024-05-14 | $85.87M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $16.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $38.16M derived: sum of 2 quarters · filed 2024-02-29 | $67.09M derived: sum of 3 quarters · filed 2024-02-29 | $87.81M 10-K · filed 2024-02-29 |
| 2022-09-30 | $21.29M 10-Q · filed 2023-11-02 | $50.22M derived: sum of 2 quarters · filed 2023-11-02 | $70.94M 10-Q · filed 2023-11-02 | $92.95M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $28.92M 10-Q · filed 2023-08-03 | $49.65M 10-Q · filed 2023-08-03 | $71.65M derived: sum of 3 quarters · filed 2023-08-03 | $88.78M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $20.73M 10-Q · filed 2023-05-04 | $42.73M derived: sum of 2 quarters · filed 2023-05-04 | $59.85M derived: sum of 3 quarters · filed 2023-05-04 | $73.89M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $22.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $39.12M derived: sum of 2 quarters · filed 2023-03-15 | $53.16M derived: sum of 3 quarters · filed 2023-03-15 | $69.04M 10-K · filed 2023-03-15 |
| 2021-09-30 | $17.12M 10-Q · filed 2022-11-03 | $31.16M derived: sum of 2 quarters · filed 2022-11-03 | $47.03M 10-Q · filed 2022-11-03 | $56.37M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $14.03M 10-Q · filed 2022-08-04 | $29.91M 10-Q · filed 2022-08-04 | $39.25M derived: sum of 3 quarters · filed 2022-08-04 | $47.88M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $15.88M 10-Q · filed 2022-05-09 | $25.21M derived: sum of 2 quarters · filed 2022-05-09 | $33.84M derived: sum of 3 quarters · filed 2022-05-09 | $41.19M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $9.34M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $17.96M derived: sum of 2 quarters · filed 2022-02-28 | $25.31M derived: sum of 3 quarters · filed 2022-02-28 | $32.60M 10-K · filed 2022-02-28 |
| 2020-09-30 | $8.63M 10-Q · filed 2021-11-10 | $15.97M derived: sum of 2 quarters · filed 2021-11-10 | $23.27M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $7.34M 10-Q · filed 2021-08-12 | $14.64M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $7.29M 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |